Long-term clinical outcomes and transcriptional analysis following partial and complete tumor SBRT plus pembrolizumab.

Authors

null

Sandeep Ramesh Bhave

University of Chicago Medicine, Chicago, IL

Sandeep Ramesh Bhave, Jason J. Luke, Jeffrey Lemons, Yuanyuan Zha, Timothy C. Carll, Thomas Krausz, Hua Liang, Linda A. Janisch, Robyn D. Hseu, Nikolai Khodarev, Ralph R. Weichselbaum, Sean Pitroda, Steven J. Chmura

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO-SITC Clinical Immuno-Oncology Symposium

Session Type

Poster Session

Session Title

Poster Session A

Track

Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies

Sub Track

Immune Checkpoints and Stimulatory Receptors

Clinical Trial Registration Number

NCT02608385

Citation

J Clin Oncol 37, 2019 (suppl 8; abstr 34)

DOI

10.1200/JCO.2019.37.8_suppl.34

Abstract #

34

Poster Bd #

C3

Abstract Disclosures

Similar Posters

Poster

2023 ASCO Annual Meeting

Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases.

Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases.

First Author: Mark Charles Korpics

Poster

2018 ASCO Annual Meeting

Phase II trial of pembrolizumab (MK-3475) in metastatic cutaneous squamous cell carcinoma (cSCC).

Phase II trial of pembrolizumab (MK-3475) in metastatic cutaneous squamous cell carcinoma (cSCC).

First Author: Ragini Reiney Kudchadkar